Comparing drug safety of hepatitis C therapies using post-market data

BACKGROUND: Hepatitis C affects about 3 % of the world’s population. In the United States, about 3.5 million have chronic hepatitis C, and it is the leading cause of liver cancer and the most common indication for liver transplantation. In the last decades, new advances in therapy have substantially...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Jing, Zhang, Xinyuan, Tong, Jiayi, Du, Jingcheng, Duan, Rui, Yang, Liu, Moore, Jason H., Tao, Cui, Chen, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6686214/
https://www.ncbi.nlm.nih.gov/pubmed/31391106
http://dx.doi.org/10.1186/s12911-019-0860-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6686214/
https://www.ncbi.nlm.nih.gov/pubmed/31391106
http://dx.doi.org/10.1186/s12911-019-0860-6

Ejemplares similares